Showing 1561-1570 of 2042 results for "".
- Alcon Launches New Technological Enhancements to the LenSx Laserhttps://modernod.com/news/alcon-launches-new-technological-enhancements-to-the-lensx-laser/2480242/Alcon will introduce new technological enhancements to the LenSx Laser at the American Society of Cataract and Refractive Surgery (ASCRS) 2018 annual meeting taking place April 13-17 in Washington, DC. The latest enhancements will provide new indications for use of the LenSx Laser during cataract
- CMS Increases Penalties Following Nearly 26K COVID-19 Nursing Home Deathshttps://modernod.com/news/cms-increases-penalties-following-nearly-26k-covid-19-nursing-home-deaths/2477852/The Trump administration has increased enforcement of states and nursing homes that have been repeat offenders for not following infection control practices, according to a FierceHealthcare
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- IOT Introduces Neochromes Agile Dark Lenseshttps://modernod.com/news/iot-introduces-neochromes-agile-dark-lenses/2481397/Spain-based IOT has introduced Neochromes Agile Dark light activated lenses. Featuring exclusive dyes from IOT, the latest agile dark lenses are darker than the company's current Neochromes, yet are designed to fade back just as quickly, according to IOT. Th
- Johnson & Johnson Vision to Launch Acuvue Oasys Max 1-Day Contact Lenses in Several Marketshttps://modernod.com/news/johnson-johnson-vision-to-launch-acuvue-oasys-max-1-day-contact-lenses-in-several-markets/2480914/Johnson & Johnson Vision announced it has received FDA clearance, Health Canada approval, and completed CE Mark activities for its latest contact lens, Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day Multifocal. The announcement comes during the 125th Annual AOA Congress and 54th<
- Staar Surgical Celebrates 2 Million Lens Milestone for Implantable Collamer Lens (ICL)https://modernod.com/news/staar-surgical-celebrates-2-million-lens-milestone-for-implantable-collamer-lens-icl/2480897/Staar Surgical announced that more than 2 million Visian Implantable Collamer lenses (ICLs) have been sold globally, including more than one and a half million of the company’s latest generation of implantable lenses–EVO Visian ICLs (EVO). New to the U.S. market, E
- The Vision Council Opens Registration for 2026 Lab Leadership Forum in Las Vegashttps://modernod.com/news/the-vision-council-opens-registration-for-2026-lab-leadership-forum-in-las-vegas/2487132/The Vision Council has opened registration for the 2026 Lab Leadership Forum, the organization’s flagship event for optical lab professionals, scheduled for Sept. 16-18, 2026, at the M Resort Spa Casino in Las Vegas. The annual
- Vital Tears and Brightstar Therapeutics Form Joint Medical Advisory Boardhttps://modernod.com/news/vital-tears-and-brightstar-therapeutics-form-joint-medical-advisory-board/2486040/Vital Tears and Brightstar Therapeutics have announced the formation of a joint Medical Advisory Board, bringing together nine leaders in ophthalmology and optometry to help guide the organizations’ expanding clinical and scientific initiatives.
- Formycon Expands Global Reach of Eylea Biosimilar FYB203 with Licensing Deals in Australia and Latin Americahttps://modernod.com/news/formycon-expands-global-reach-of-eylea-biosimilar-fyb203-with-licensing-deals-in-australia-and-latin-america/2484186/Formycon AG announced that its licensing partner Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea¹ biosimilar FYB203 (aflibercept), has signed two new exclusive agreements to broaden the product’s internat
- Formycon Expands European Footprint for Aflibercept Biosimilar FYB203 with Horus Pharma Dealhttps://modernod.com/news/formycon-expands-european-footprint-for-aflibercept-biosimilar-fyb203-with-horus-pharma-deal/2484146/Formycon announced that Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea biosimilar FYB203 (aflibercept), has entered into a new semi-exclusive license agreement with Horus Pharma. The deal grants Horus the right to